Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
EvaluatePharma
Evaluate Omnium
Japan Drug Forecasts
European Drug Forecasts
Epi Analyzer
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
PDL BioPharma
May 13, 2015
Asco preview – The eloquence of elotuzumab
March 20, 2014
Upcoming events: US panels to discuss new antibiotics and Mannkind’s Afrezza
September 03, 2013
ESC – Heart failure miss knocks wind from Cytokinetics
August 30, 2012
Genmab scores big J&J deal for myeloma antibody
February 21, 2012
Takeda results point to novel ulcerative colitis treatment
September 14, 2010
Seattle Genetics brushes off lintuzumab trial and focuses on brentuximab vedotin
July 13, 2010
EP Vantage Interview – New Genmab CEO aiming to turn tide in its favour
June 23, 2010
Diamyd continues winning streak with J&J deal
April 27, 2010
Event - Seattle Genetics seeking niche indication from new AML trial
March 10, 2010
Abbott dons white knight armour and rides to Facet's rescue
December 18, 2009
Facet rebuffs Biogen but will white knight emerge?
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
December 10, 2020
Evaluate Vantage 2021 Preview
July 29, 2020
Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020
Editor's Picks
January 18, 2021
Aducanumab tops 2021’s biggest potential launches
January 19, 2021
The pandemic releases its grip on clinical trials
January 21, 2021
2020 drug approvals rise despite Covid-19
January 20, 2021
Glaxo joins the Covid-19 delay queue
January 21, 2021
Merck KGaA’s dual immuno-oncology weapon misfires
